One- and two-stage design proposals for a phase II trial comparing three active treatments with control using an ordered categorical endpoint.
Phase II clinical trials are performed to investigate whether a novel treatment shows sufficient promise of efficacy to justify its evaluation in a subsequent definitive phase III trial, and they are often also used to select the dose to take forward. In this paper we discuss different design proposals for a phase II trial in which three active treatment doses and a placebo control are to be compared in terms of a single-ordered categorical endpoint. The sample size requirements for one-stage and two-stage designs are derived, based on an approach similar to that of Dunnett. Detailed computations are prepared for an illustrative example concerning a study in stroke. Allowance for early stopping for futility is made. Simulations are used to verify that the specified type I error and power requirements are valid, despite certain approximations used in the derivation of sample size. The advantages and disadvantages of the different designs are discussed, and the scope for extending the approach to different forms of endpoint is considered.
Whitehead
John
J
Department of Mathematics and Statistics, Lancaster University, Lancaster, U.K. j.whitehead@lancaster.ac.uk
Jaki
Thomas
T
D000465:Algorithms; D017322:Clinical Trials, Phase II as Topic / Q000379:methods*; D003198:Computer Simulation; D015340:Epidemiologic Research Design; D006801:Humans; D018447:Medical Futility; D015233:Models, Statistical; D011336:Probability; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D018401:Sample Size; D018709:Statistics, Nonparametric; D020521:Stroke / Q000188:drug therapy; D016896:Treatment Outcome